Cargando…
A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study
The aim of this phase I study was to assess feasibility, pharmacokinetics and toxicity of methoxymorpholino doxorubicin (MMRDX or PNU-152243) administered as a 3 h intravenous infusion once every 4 weeks. Fourteen patients with intrinsically anthracycline-resistant tumours received 37 cycles of MMRD...
Autores principales: | Fokkema, E, Verweij, J, van Oosterom, A T, Uges, D R A, Spinelli, R, Valota, O, de Vries, E G E, Groen, H J M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374418/ https://www.ncbi.nlm.nih.gov/pubmed/10732743 http://dx.doi.org/10.1054/bjoc.1999.0996 |
Ejemplares similares
-
Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
por: Bakker, M., et al.
Publicado: (1998) -
PnuT uses a facilitated diffusion mechanism for thiamine uptake
por: Jaehme, Michael, et al.
Publicado: (2018) -
A PNU-Based Methodology to Improve the Reliability of Biometric Systems
por: Capasso, Paola, et al.
Publicado: (2022) -
Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study.
por: Groen, H. J., et al.
Publicado: (1995) -
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)
por: Bissett, D, et al.
Publicado: (2004)